Papers
1
Total Citations
62
H-Index
1
About
Gary J. Miller is a prominent urologic oncologist whose research has centered on the treatment of high-risk, locally advanced prostate cancer. His most significant contribution stems from his leadership in the Phase II Southwest Oncology Group (SWOG) Study 9109, which investigated neoadjuvant therapy before radical prostatectomy for clinical T3/T4 prostate cancer. This landmark work, published in the *Journal of Urology*, provided critical long-term data on the safety and feasibility of combining systemic therapy with surgery in patients with bulky disease—a population often considered inoperable at the time. The study’s 5-year follow-up, which has garnered over 60 citations, helped reshape clinical thinking by demonstrating that aggressive local control could be achieved with acceptable morbidity. Miller’s research has been instrumental in advancing multidisciplinary approaches to high-stage prostate cancer, bridging the gap between medical and surgical oncology. His work continues to inform treatment paradigms for patients with locally advanced disease, underscoring his lasting impact on urologic oncology and clinical trial design.
Research Focus
Key Achievements
Top Papers
- 1